Our plan is to turn around the Chiron vaccines business, which will require investments in R&D and manufacturing to increase quality and capacity,

I am pleased with the overall strong performance of our business in the third quarter, particularly the dynamic growth of Pharmaceuticals.

Market growth in 2006 will slow down somewhat. I expect that we will be able to continue to gain market share.

At present, no collaboration has been discussed with Roche management, although we hope that over time we will be able to explore areas of collaboration.

We will be evaluating that (a manufacturing base) as we move forward and our business grows.

Export volumes and manufacturing output are playing more important roles in affecting the business mood.